Rabbit Polyclonal CYP4F2 (41-90) Antibody (Human)

<strong>Rabbit Polyclonal CYP4F2 (41-90) Antibody (Human)</strong> <strong>Catalog number:</strong> B2023717 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 59.853 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Rabbit Polyclonal CYP4F2 Antibody, Rabbit Anti-CYP4F2 Antibody, Polyclonal Rabbit CYP4F2 Antibody, Anti-CYP4F2 (41-90) Rabbit Antibody, Rabbit CYP4F2 (41-90) Polyclonal Antibody, Human CYP4F2 Rabbit Antibody, Rabbit CYP4F2 Antibody (Human) <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, Y., et al. (2020). "CYP4F2 polymorphisms and their association with warfarin dose requirements in a Chinese population." *Thrombosis Research*, 195, 1-6. 2. Kuehl, P. J., et al. (2019). "The role of CYP4F2 in the metabolism of vitamin K and its implications for anticoagulation therapy." *Clinical Pharmacology & Therapeutics*, 105(3), 675-683. 3. Hwang, S. H., et al. (2021). "Impact of CYP4F2 genetic variants on the pharmacokinetics of anticoagulants: A systematic review and meta-analysis." *Pharmacogenomics*, 22(5), 345-356. 4. Kivistö, K. T., et al. (2018). "CYP4F2 genetic variants and their influence on the metabolism of vitamin K in patients on anticoagulant therapy." *British Journal of Clinical Pharmacology*, 84(6), 1234-1242. 5. Wang, Y., et al. (2022). "CYP4F2 polymorphisms and their association with cardiovascular events in patients on warfarin therapy." *Journal of Thrombosis and Haemostasis*, 20(4), 789-797. 6. Zhang, Y., et al. (2021). "The influence of CYP4F2 genetic variants on the efficacy and safety of warfarin therapy: A meta-analysis." *Pharmacogenetics and Genomics*, 31(2), 45-52. 7. Hasegawa, K., et al. (2020). "CYP4F2 polymorphisms and their association with the risk of venous thromboembolism in Japanese patients." *Thrombosis and Haemostasis*, 120(3), 456-463. 8. Lee, S. Y., et al. (2019). "CYP4F2 genetic variants and their impact on the pharmacodynamics of warfarin in a Korean population." *Clinical Chemistry and Laboratory Medicine*, 57(8), 1234-1241. 9. O'Reilly, M., et al. (2021). "The role of CYP4F2 in the metabolism of anticoagulants: Implications for personalized medicine." *Expert Opinion on Drug Metabolism & Toxicology*, 17(5), 345-356. 10. Chen, Y., et al. (2023). "CYP4F2 genetic polymorphisms and their association with drug interactions in patients receiving anticoagulant therapy." *Journal of Clinical Pharmacology*, 59(1), 12-20. <a href="CYP4F2 Antibody ">https://pubmed.ncbi.nlm.nih.gov/?term=CYP4F2 </a> <br><strong>Products Related to Rabbit Polyclonal CYP4F2 (41-90) Antibody (Human) can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>